Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers

The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein. BET protein alterations are associated with some solid tumor cancers, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Martin V., Loof, Lydia, Falchook, Gerald S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208386/
https://www.ncbi.nlm.nih.gov/pubmed/35756176
http://dx.doi.org/10.4103/JIPO.JIPO_2_20
Descripción
Sumario:The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein. BET protein alterations are associated with some solid tumor cancers, including nuclear protein in testis midline carcinoma. BET protein has a role in carcinogenesis and in the regulation of the cell cycle. A number of BET inhibitors have entered clinical trials. This review discusses the results of BET inhibitor clinical trials in solid tumor cancers.

Ejemplares similares